

chain nodes :

13 14 15 16 20 21 22 43 47

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 23 24 25 26 27 29 30 31 32
 33 34 35 36 37 38 39 40 50 51 52 53 54 55 57 58 59 61 62
 63 64 65 66 67 68 69

chain bonds :

2-13 5-14 9-20 12-13 14-15 14-16 20-21 21-22 22-47

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 23-24
 23-27 24-25 25-26 26-27 29-30 29-34 30-31 31-32 32-33 33-34 35-36
 35-40 36-37 37-38 38-39 39-40 50-51 50-55 51-52 52-53 53-54 54-55
 57-58 57-59 58-59 61-62 61-66 62-63 63-64 64-65 64-67 65-66 65-69
 67-68 68-69

exact/norm bonds :

1-2 1-6 2-3 2-13 3-4 4-5 5-6 5-14 7-8 7-12 8-9 9-10 9-20 10-11
 11-12 12-13 14-15 14-16 20-21 21-22 22-47 23-24 23-27 24-25 25-26
 26-27 35-36 35-40 36-37 37-38 38-39 39-40 57-58 57-59 58-59 64-67
 65-69 67-68 68-69

normalized bonds :

29-30 29-34 30-31 31-32 32-33 33-34 50-51 50-55 51-52 52-53 53-54
 54-55 61-62 61-66 62-63 63-64 64-65 65-66

isolated ring systems :

containing 1 : 7 : 23 :

G1:C,N

G2:[*1],[*2],[*3],[*4]

Connectivity :

43:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
 10:Atom

1:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 20:CLASS
21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 29:Atom
30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 43:CLASS 47:CLASS 50:Atom 51:Atom 52:Atom
53:Atom 54:Atom 55:Atom 57:Atom 58:Atom 59:Atom 61:Atom 62:Atom
63:Atom 64:Atom 65:Atom 66:Atom 67:Atom 68:Atom 69:Atom

10581164

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

Updated Search

10581164

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:10:29 ON 01 FEB 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.05

1.05

FILE 'REGISTRY' ENTERED AT 13:13:16 ON 01 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5

DICTIONARY FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\121298.str

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 13:13:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3245 TO ITERATE

61.6% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

39 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 61484 TO 68316

Updated Search

10581164

PROJECTED ANSWERS: 788 TO 1742

L2 39 SEA SSS SAM L1

=> s l1 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 13:13:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 65772 TO ITERATE

100.0% PROCESSED 65772 ITERATIONS
SEARCH TIME: 00.00.01

1207 ANSWERS

L3 1207 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

173.15

FILE 'HCAPLUS' ENTERED AT 13:13:50 ON 01 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Feb 2007 VOL 146 ISS 6

FILE LAST UPDATED: 31 Jan 2007 (20070131/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 181 L3

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.60

175.75

FILE 'REGISTRY' ENTERED AT 13:13:57 ON 01 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

Updated Search

10581164

STRUCTURE FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5
DICTIONARY FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s 14
L5 1207 L3

=>
Uploading C:\Documents and Settings\brobinson1\My
Documents\stnweb\Queries\rtraaaxtr.str

L6 STRUCTURE UPLOADED

=> s 16
SAMPLE SEARCH INITIATED 13:22:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 445 TO ITERATE

100.0% PROCESSED 445 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7635 TO 10165
PROJECTED ANSWERS: 0 TO 0


L7 0 SEA SSS SAM L6

=> s 16 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 13:22:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8421 TO ITERATE

100.0% PROCESSED 8421 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L8 0 SEA SSS FUL L6

Updated Search



```

chain nodes :
  13 14 15 16 20 21 22 23 27
ring nodes :
  1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
  2-13 5-14 9-20 12-13 14-15 14-16 20-21 21-22 22-27
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
  1-2 1-6 2-3 2-13 3-4 4-5 5-6 5-14 7-8 7-12 8-9 9-10 9-20 10-11
  11-12 12-13 14-15 14-16 20-21 21-22 22-27
isolated ring systems :
  containing 1 : 7 :

```

G1:C,N

G2:cy, [*1]

Connectivity :

23:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
 10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 20:CLASS
 21:CLASS 22:CLASS 23:CLASS 27:CLASS

10581164

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 6 NOV 10 CA/CAPLUS F-Term thesaurus enhanced
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 8 NOV 20 CA/CAPLUS to MARPAT accession number crossover limit increased
to 50,000
NEWS 9 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 10 DEC 11 CAS REGISTRY chemical nomenclature enhanced
NEWS 11 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and
functionality
NEWS 13 DEC 18 CA/CAPLUS pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 14 DEC 18 CA/CAPLUS patent kind codes updated
NEWS 15 DEC 18 MARPAT to CA/CAPLUS accession number crossover limit increased
to 50,000
NEWS 16 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 17 DEC 27 CA/CAPLUS enhanced with more pre-1907 records
NEWS 18 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 20 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 21 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 23 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 24 JAN 29 PHAR reloaded with new search and display fields
NEWS 25 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

Updated Search

10581164

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:10:29 ON 01 FEB 2007

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.05	1.05

FILE 'REGISTRY' ENTERED AT 13:13:16 ON 01 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5
DICTIONARY FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\121298.str

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 13:13:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3245 TO ITERATE

61.6% PROCESSED	2000 ITERATIONS	39 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)		
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 61484 TO 68316

Updated Search

10581164

PROJECTED ANSWERS: 788 TO 1742

L2 39 SEA SSS SAM L1

=> s l1 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 13:13:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 65772 TO ITERATE

100.0% PROCESSED 65772 ITERATIONS

1207 ANSWERS

SEARCH TIME: 00.00.01

L3 1207 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

173.15

FILE 'HCAPLUS' ENTERED AT 13:13:50 ON 01 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Feb 2007 VOL 146 ISS 6

FILE LAST UPDATED: 31 Jan 2007 (20070131/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification..

=> s l3

L4 181 L3

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.60

175.75

FILE 'REGISTRY' ENTERED AT 13:13:57 ON 01 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

Updated Search

10581164

STRUCTURE FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5
DICTIONARY FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s 14
L5 1207 L3

=>
Uploading C:\Documents and Settings\brobinson1\My
Documents\stnweb\Queries\rtraaaxtr.str

L6 STRUCTURE UPLOADED

=> s 16
SAMPLE SEARCH INITIATED 13:22:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 445 TO ITERATE

100.0% PROCESSED 445 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7635 TO 10165
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s 16 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 13:22:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8421 TO ITERATE

100.0% PROCESSED 8421 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L8 0 SEA SSS FUL L6

=>
Uploading C:\Documents and Settings\brobinson1\My
Documents\stnweb\Queries\3awe4343r.str

L9 STRUCTURE UPLOADED

=> s 19

Updated Search

10581164

SAMPLE SEARCH INITIATED 13:25:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2933 TO ITERATE

68.2% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 55412 TO 61908
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> s l9 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 13:25:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 59572 TO ITERATE

100.0% PROCESSED 59572 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.02

L11 13 SEA SSS FUL L9

=> file hcaplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	351.85	527.60

FILE 'HCAPLUS' ENTERED AT 13:25:17 ON 01 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Feb 2007 VOL 146 ISS 6
FILE LAST UPDATED: 31 Jan 2007 (20070131/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l11
L12 5 L11

=> d l12, ibib abs hitstr, 1-5


Updated Search

10581164

L12 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:588876 HCAPLUS
DOCUMENT NUMBER: 143:115448
TITLE: Nicotinamide derivatives preparation as opioid receptor antagonists
INVENTOR(S): Benesh, Dana Rae; Blanco-Pillado, Maria-Jesus
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061442	A1	20050707	WO 2004-US38227	20041206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303790	A1	20050707	AU 2004-303790	20041206
CA 2549009	A1	20050707	CA 2004-2549009	20041206
EP 1697307	A1	20060906	EP 2004-811079	20041206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1890208	A	20070103	CN 2004-80036471	20041206
US 2007010558	A1	20070111	US 2006-581164	20060531
PRIORITY APPLN. INFO.:			US 2003-529061P	P 20031212
			WO 2004-US38227	W 20041206
OTHER SOURCE(S):			MARPAT 143:115448	
GI				



AB Nicotinamide derivs. were prepd. for use in the treatment, prevention or amelioration of obesity and related diseases. E.g., I was prepared starting from 3,3-dimethyl-1,5-dioxaspiro[5.5]undecan-9-one through a number of reaction sequences. I and a number of other derivs. were tested with the GTP- γ -S binding assay and ex vivo receptor binding.

IT 857048-52-3P 857048-53-4P 857048-54-5P
857048-55-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

Updated Search


10581164

(Uses)

(nicotinamide derivs. preparation as opioid receptor antagonists)


RN 857048-52-3 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[[4-[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 857048-53-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[[4-[(3-methylbutyl)amino]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 857048-54-5 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[[4-[[2-(2-thienyl)ethyl]amino]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)



RN 857048-55-6 HCAPLUS

CN Benzamide, 4-[[4-[(3-phenylpropyl)amino]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)



IT 857048-56-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nicotinamide derivs. preparation as opioid receptor antagonists)


RN 857048-56-7 HCAPLUS

Updated Search

10581164

CN 3-Pyridinecarboxamide, 6-[[trans-4-[(phenylmethyl)amino]cyclohexyl]oxy]-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:570983 HCAPLUS

DOCUMENT NUMBER: 143:97274

TITLE: Preparation of piperidines as chemokine receptor, particularly CCR5, modulators for treatment of inflammatory and autoimmune diseases

INVENTOR(S): Bridger, Gary J.; Zhou, Yuanxi; Skerlj, Renato

PATENT ASSIGNEE(S): Anormed Inc., Can.

SOURCE: PCT Int. Appl., 384 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005059107	A2	20050630	WO 2004-US41865	20041213
WO 2005059107	A3	20060105		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2548393	A1	20050630	CA 2004-2548393	20041213
EP 1708703	A2	20061011	EP 2004-814091	20041213
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			

PRIORITY APPLN. INFO.: US 2003-528975P P 20031211
WO 2004-US41865 W 20041213

OTHER SOURCE(S): MARPAT 143:97274
GI

Updated Search



AB Title compds. I [wherein X = C, N; Y = O if X = C, or a bond if X = N; Z = (CH₂)_n; n = 0-1; R₁ = (un)substituted hetero/aryl; R₂ = (un)substituted hetero/aryl, N:(alkyl); R₃ = (un)substituted hetero/aryl, or a Ph fused with a 5- or 6-membered heterocycle; R₄ = H, alkyl; and their pharmaceutically acceptable salts] were prepared as chemokine receptor, particularly CCR5, modulators for treatment of inflammatory and autoimmune diseases. For example, coupling of 2,4-dimethyl-N-oxonicotinic acid with [3-[4-[(4-bromophenyl)phenoxy)methyl]piperidin-1-yl]butylamine (preparation given) gave II in 82% yield. I exhibited IC₅₀'s in the range of 0.01 nM to 50 μM in an assay for inhibition of HIV-1 using PMBC and R5. Compds. I demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

IT 856937-05-8P, 4,6-Dimethylpyrimidine-5-carboxylic acid [(R)-3-[4-[[4-(4-carbamoylphenoxy)phenyl](thien-3-ylmethyl)amino]piperidin-1-yl]butyl]amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(CCR5 modulator; preparation of piperidines as chemokine receptor modulators for treatment of inflammatory and autoimmune diseases)

RN 856937-05-8 HCAPLUS

CN 5-Pyrimidinecarboxamide, N-[(3R)-3-[4-[[4-[4-(aminocarbonyl)phenoxy]phenyl](3-thienylmethyl)amino]-1-piperidinyl]butyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10581164



L12 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:309175 HCAPLUS

DOCUMENT NUMBER: 143:90722

TITLE: Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

AUTHOR(S): Johnson, Michael P.; Barda, David; Britton, Thomas C.; Emkey, Renee; Hornback, William J.; Jagdmann, G. Erik; McKinzie, David L.; Nisenbaum, Eric S.; Tizzano, Joseph P.; Schoepp, Darryle D.

CORPORATE SOURCE: Lilly Research Laboratories, Lilly Corp. Cent., Eli Lilly and Company, IN, 46285, USA

SOURCE: Psychopharmacology (Berlin, Germany) (2005), 179(1), 271-283

CODEN: PSCHDL; ISSN: 0033-3158

PUBLISHER: Springer GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To increase subtype selectivity and provide a novel means to alter receptor function, the authors discovered and characterization potentiators for the metabotropic glutamate 2 receptor (mGlu2). A class of 3-pyridylmethylsulfonamides (e.g., 3-MPPTS; 2,2,2-trifluoro-N-[3-(2-methoxyphenoxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide) were found to be potent, subtype-selective potentiators of human and rat mGlu2. The sulfonamides increased agonist potency in functional assays but did not displace orthosteric radiolabeled antagonist or agonist binding to cloned mGlu2 receptors. Rather, the modulators increased the affinity of most of the orthosteric agonists including glutamate, DCG-IV ((2S,2'R,3'R)-2-(2',3'-dicarboxylcyclopropyl)glycine), and LY354740 (1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicarboxylate monohydrate). In striatal brain slices, LY354740 inhibited evoked excitatory postsynaptic potentials (EPSPs) equally well following either a low- (0.06 Hz) or high (4 Hz)-frequency stimulation of corticostriatal afferents. In contrast, the mGlu2 potentiator cyPPTS (2,2,2-trifluoro-N-[3-(cyclopentyloxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide) inhibited striatal EPSPs only at higher frequencies of stimulation (2 and 4 Hz). Several sulfonamides including 4-MPPTS, 4-APPEs (N-[4-(4-carboxamidophenoxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide hydrochloride monohydrate), and/or

Updated Search

10581164

CBiPES (N-[4'-cyano-biphenyl-3-yl]-N-(3-pyridinylmethyl)-ethanesulfonamide hydrochloride) were tested in mGlu2/3 agonist-sensitive rodent model(s) of anxiety and psychosis. As seen with LY354740, both 4-MPPTS and 4-APPES were efficacious in a rat fear-potentiated startle paradigm. Likewise in mice, CBiPES attenuated a stress-induced hyperthermia and PCP-induced hyperlocomotor activity. Furthermore, CBiPES mediated alteration in PCP-induced hyperlocomotor activity was sensitive to mGlu2/3 antagonist pretreatment. Taken together, the data indicate mGlu2 receptor potentiators have a unique use-dependent effect on presynaptic glutamate release, and show efficacy in several mGlu2/3-sensitive animal models of psychiatric disorders.


IT 856702-39-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mGlu2 receptor potentiators on presynaptic glutamate release in preclin. anxiety and psychosis models)

RN 856702-39-1 HCAPLUS

CN Benzamide, 4-[4-[(ethylsulfonyl)(3-pyridinylmethyl)amino]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: . 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:267241 HCAPLUS

DOCUMENT NUMBER: 140:303538

TITLE: Preparation of [[(aminoalkyl)aryl]oxy]nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions

INVENTOR(S): Blanco-Pillado, Maria-Jesus; Chappell, Mark Donald; Garcia De la Torre, Marta; Diaz Buezo, Nuria; Fritz, James Erwin; Holloway, William Glen; Matt, James Edward, Jr.; Mitch, Charles Howard; Pedregal-Tercero, Concepcion; Quimby, Steven James; Siegel, Miles Goodman; Smith, Dana Rae; Stucky, Russell Dean; Takeuchi, Kumiko; Thomas, Elizabeth Marie; Wolfe, Chad Nolan

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 559 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

Updated Search


10581164

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026305	A1	20040401	WO 2003-US26300	20030917
WO 2004026305	A9	20040513		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499690	A1	20040401	CA 2003-2499690	20030917
AU 2003269980	A1	20040408	AU 2003-269980	20030917
BR 2003014308	A	20050705	BR 2003-14308	20030917
EP 1562595	A1	20050817	EP 2003-751877	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681498	A	20051012	CN 2003-822241	20030917
JP 2006511474	T	20060406	JP 2004-537682	20030917
US 2006217372	A1	20060928	US 2005-526960	20050303
IN 2005KN00457	A	20060303	IN 2005-KN457	20050318
NO 2005001871	A	20050418	NO 2005-1871	20050418
PRIORITY APPLN. INFO.:			US 2002-412158P	P 20020919
			WO 2003-US26300	W 20030917
OTHER SOURCE(S):			MARPAT 140:303538	
GI				



I



II

AB Title diaryl ethers I [wherein X1-X10 = independently C, CH, or N; provided that each of rings A or B has no more than 2 N atoms; E = O or

Updated Search

NH; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, (aryl)heterocyclyl, (cyclo)alkylheterocyclyl, (cyclo)alkanoylalkyl, aroylalkyl, aryloxyalkyl, benzhydryl, bicyclyl(alkyl), benzoyl(alkyl), alkoxyalkyl, alkoxycarbonyl, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, cycloalkylalkyl, carboxyalkyl, carbamoylalkyl, etc.; R3 and R3' = independently H, alkyl, alkenyl, alkynyl, (alkyl)aryl, or alkylcycloalkyl; R4 and R5 = independently H, (halo)alkyl, alkenyl, alkynyl, alkoxy(halo)alkyl, thioalkyl, halo, aryl(alkyl), alkanoyl, alkoxycarbonyl, aminoalkyl, cycloalkylalkyl, etc.; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, alkanoyl, OH, alkoxy, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, aryl(alkyl), carbamoyl(alkyl), etc.; m = 1-3; n = 0-3; p = 0-3; or pharmaceutically acceptable salts, solvates, enantiomers, racemates, diastereomers, or mixts. thereof] were prepared as μ -, κ -, and δ -opioid receptor antagonists. For example, reductive amination of 6-(2-fluoro-4-formylphenoxy)nicotinamide and 3-methylbutylamine provided II (99%). The latter inhibited ex vivo binding of [3H]-diprenorphine in rat striatum/nucleus accumbens by >65% at a concentration of 7 mg/kg. In an acute feeding rat obesity assay, II

suppressed

opioid receptors at a dose of 0.3 μ g/kg. In addition, diet-induced obese rats achieved an energy balance (caloric intake minus utilization) of -81 kcal/kg/day upon administration of 0.3 mg/kg p.o. of II in an indirect calorimetry assay. Thus, I and their pharmaceutical comps. are useful for the treatment, prevention, or amelioration of obesity and related diseases.


IT 676495-22-0P, 4-[4-(3-Phenylpropylamino)phenoxy]benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)

RN 676495-22-0 HCAPLUS

CN Benzamide, 4-[4-[(3-phenylpropyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:581845 HCAPLUS

DOCUMENT NUMBER: 135:152723

TITLE: Preparation of N-phenyl-N-alkylsulfonyl(pyridylmethyl)amines as potentiators of glutamate receptors


INVENTOR(S): Coleman, Darrell Stephen; Jagdmann, Gunnar Erik Junior; Johnson, Kirk Willis; Johnson, Michael Parvin; Large, Thomas Hallett; Monn, James Allen; Schoepp, Darryle Darwin; Tizzano, Joseph Patrick; Barda, David Anthony; Britton, Thomas Charles; Dressman, Bruce

10581164


Anthony; Fichtner, Michael William; Henry, Steven
 Scott; Hornback, William Joseph
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 247 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056990	A2	20010809	WO 2001-US643	20010122
WO 2001056990	A3	20020425		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1255735 A2 20021113 EP 2001-906521 20010122 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR US 2004006114 A1 20040108 US 2002-182961 20021120 US 6800651 B2 20041005 PRIORITY APPLN. INFO.: US 2000-180047P P 20000203 US 2000-180089P P 20000203 WO 2001-US643 W 20010122				

OTHER SOURCE(S): MARPAT 135:152723
 GI



I



II

AB The title compds. [I; R1 = COR3, CO2R4, SO2R5 (wherein R3 = alkyl, cycloalkyl; R4 = alkyl, cycloalkyl; R5 = alkyl, cycloalkyl, fluorinated alkyl); R2 = H, OH, alkyl, etc.; or two R2 are taken together, on adjacent

Updated Search

10581164


position, to form a fused cycloalkyl or methylenedioxy ring; R6 = H, alkyl, alkoxy, etc.; X = a bond, CH2, (CH2)2, CH(alkyl); Y = a bond, CH2, (CH2)2, etc.] and their pharmaceutically acceptable salts which are potentiators of metabotropic glutamate receptor function, in particular mGlu2 and/or mGlu3 receptors, and therefore useful in treating migraine, anxiety, epilepsy and schizophrenia, were prepared and formulated. Thus, reductive alkylation of 3-(2-methoxyphenoxy)aniline (preparation given) with pyridine-3-carboxaldehyde in the presence of NaBH4 followed by alkylation of the resulting N-[3-(2-methoxyphenoxy)phenyl]pyrid-3-methylamine with F3CCH2SO2Cl afforded the amine II which showed to act at a site other than the glutamate recognition site to potentiate the effects of glutamate at mGlu receptors (data given).

IT 353233-13-3P 353234-76-1P 353235-43-5P
353235-49-1P 353237-68-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenyl-N-alkylsulfonyl(pyridylmethyl)amines as potentiators of glutamate receptors)

RN 353233-13-3 HCAPLUS

CN Benzamide, 4-[4-[(ethylsulfonyl)(3-pyridinylmethyl)amino]phenoxy]-, hydrochloride (10:11) (9CI) (CA INDEX NAME)




●11/10 HCl

RN 353234-76-1 HCAPLUS


CN Benzamide, 4-[4-[(ethylsulfonyl)(3-pyridinylmethyl)amino]phenoxy]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

10581164




● HCl

RN 353235-43-5 HCAPLUS
CN Benzamide, 4-[4-[(ethylsulfonyl)(3-pyridinylmethyl)amino]phenoxy]- (9CI)
(CA INDEX NAME)




RN 353235-49-1 HCAPLUS
CN Benzamide, 4-[4-[(ethylsulfonyl)(3-pyridinylmethyl)amino]phenoxy]-3-fluoro- (9CI)
(CA INDEX NAME)



RN 353237-68-0 HCAPLUS
CN Benzamide, 3-fluoro-4-[4-[(3-pyridinylmethyl)[(2,2,2-trifluoroethyl)sulfonyl]amino]phenoxy]- (9CI)
(CA INDEX NAME)

Updated Search

10581164



=> file caold
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
28.95	556.55

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.90	-3.90

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 13:25:31 ON 01 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 13:10:29 ON 01 FEB 2007)

FILE 'REGISTRY' ENTERED AT 13:13:16 ON 01 FEB 2007

L1 STRUCTURE UPLOADED
L2 39 S L1
L3 1207 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 13:13:50 ON 01 FEB 2007

L4 181 S L3

FILE 'REGISTRY' ENTERED AT 13:13:57 ON 01 FEB 2007

L5 1207 S L4

Updated Search



10581164

L6 STRUCTURE UPLOADED
L7 0 S L6
L8 0 S L6 FULL
L9 STRUCTURE UPLOADED
L10 0 S L9
L11 13 S L9 FULL

FILE 'HCAPLUS' ENTERED AT 13:25:17 ON 01 FEB 2007
L12 5 S L11

FILE 'CAOLD' ENTERED AT 13:25:31 ON 01 FEB 2007

=> s l11
L13 0 L11



chain nodes :

13 14 15 16 20 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

2-13 5-14 9-20 12-13 14-15 14-16 20-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

1-2 1-6 2-3 2-13 3-4 4-5 5-6 5-14 7-8 7-12 8-9 9-10 9-20 10-11
11-12 12-13 14-15 14-16 20-21

isolated ring systems :

containing 1 : 7 :

G1:C,N

G2:Cy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 20:CLASS
21:CLASS

10581164

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxr

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAOLD' AT 13:39:24 ON 01 FEB 2007
FILE 'CAOLD' ENTERED AT 13:39:24 ON 01 FEB 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	557.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.90	557.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

FILE 'REGISTRY' ENTERED AT 13:40:09 ON 01 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5
DICTIONARY FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\34345q.str

Updated Search

10581164

L14 STRUCTURE UPLOADED

=> d l14

L14 HAS NO ANSWERS

L14 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l14

SAMPLE SEARCH INITIATED 13:41:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 757 TO ITERATE

100.0% PROCESSED 757 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 13490 TO 16790

PROJECTED ANSWERS: 1 TO 80

L15 1 SEA SSS SAM L14

=> s l14 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 13:41:20 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 15385 TO ITERATE

100.0% PROCESSED 15385 ITERATIONS

15 ANSWERS

SEARCH TIME: 00.00.01

L16 15 SEA SSS FUL L14

=> file caold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

730.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.90

FILE 'CAOLD' ENTERED AT 13:41:24 ON 01 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

Updated Search

10581164

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 116

L17 0 L16

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.45	730.45

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-3.90

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 13:41:30 ON 01 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Feb 2007 VOL 146 ISS 6

FILE LAST UPDATED: 31 Jan 2007 (20070131/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 116

L18 7 L16

=> d 118, ibib abs hitstr, 1-7

L18 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:588876 HCAPLUS

DOCUMENT NUMBER: 143:115448

TITLE: Nicotinamide derivatives preparation as opioid receptor antagonists

INVENTOR(S): Benesh, Dana Rae; Blanco-Pillado, Maria-Jesus

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

Updated Search

10581164

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061442	A1	20050707	WO 2004-US38227	20041206
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2004303790	A1	20050707	AU 2004-303790	20041206
CA 2549009	A1	20050707	CA 2004-2549009	20041206
EP 1697307	A1	20060906	EP 2004-811079	20041206
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS	
CN 1890208	A	20070103	CN 2004-80036471	20041206
US 2007010558	A1	20070111	US 2006-581164	20060531
PRIORITY APPLN. INFO.:			US 2003-529061P	P 20031212
			WO 2004-US38227	W 20041206
OTHER SOURCE(S):		MARPAT 143:115448		
GI				



I

AB Nicotinamide derivs. were prepd. for use in the treatment, prevention or amelioration of obesity and related diseases. E.g., I was prepared starting from 3,3-dimethyl-1,5-dioxaspiro[5.5]undecan-9-one through a number of reaction sequences. I and a number of other derivs. were tested with the GTP-γ-S binding assay and ex vivo receptor binding.

IT 857048-52-3P 857048-53-4P 857048-54-5P 857048-55-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nicotinamide derivs. preparation as opioid receptor antagonists)


RN 857048-52-3 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[[4-[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)


10581164




RN 857048-53-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[[4-[(3-methylbutyl)amino]cyclohexyl]oxy]- (9CI)
(CA INDEX NAME)



RN 857048-54-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[[4-[[2-(2-thienyl)ethyl]amino]cyclohexyl]oxy]-
(9CI) (CA INDEX NAME)



RN 857048-55-6 HCAPLUS
CN Benzamide, 4-[[4-[(3-phenylpropyl)amino]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




IT 857048-56-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nicotinamide derivs. preparation as opioid receptor antagonists)
RN 857048-56-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[[trans-4-[(phenylmethyl)amino]cyclohexyl]oxy]-
(9CI) (CA INDEX NAME)

Relative stereochemistry.

Updated Search

10581164



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:570983 HCAPLUS

DOCUMENT NUMBER: 143:97274

TITLE: Preparation of piperidines as chemokine receptor, particularly CCR5, modulators for treatment of inflammatory and autoimmune diseases

INVENTOR(S): Bridger, Gary J.; Zhou, Yuanxi; Skerlj, Renato

PATENT ASSIGNEE(S): Anormed Inc., Can.

SOURCE: PCT Int. Appl., 384 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005059107	A2	20050630	WO 2004-US41865	20041213
WO 2005059107	A3	20060105		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2548393	A1	20050630	CA 2004-2548393	20041213
EP 1708703	A2	20061011	EP 2004-814091	20041213
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU.			
PRIORITY APPLN. INFO.:			US 2003-528975P	P 20031211
			WO 2004-US41865	W 20041213

OTHER SOURCE(S): MARPAT 143:97274

GI



AB Title compds. I [wherein X = C, N; Y = O if X = C, or a bond if X = N; Z = (CH₂)_n; n = 0-1; R₁ = (un)substituted hetero/aryl; R₂ = (un)substituted hetero/aryl, N:(alkyl); R₃ = (un)substituted hetero/aryl, or a Ph fused with a 5- or 6-membered heterocycle; R₄ = H, alkyl; and their pharmaceutically acceptable salts] were prepared as chemokine receptor, particularly CCR5, modulators for treatment of inflammatory and autoimmune diseases. For example, coupling of 2,4-dimethyl-N-oxonicotinic acid with [3-[4-[(4-bromophenyl)phenoxy]methyl]piperidin-1-yl]butylamine (preparation given) gave II in 82% yield. I exhibited IC₅₀'s in the range of 0.01 nM to 50 μM in an assay for inhibition of HIV-1 using PMBC and R5. Compds. I demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

IT 856937-05-8P, 4,6-Dimethylpyrimidine-5-carboxylic acid
[(R)-3-[4-[[4-(4-carbamoylphenoxy)phenyl](thien-3-ylmethyl)amino]piperidin-1-yl]butyl]amide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CCR5 modulator; preparation of piperidines as chemokine receptor modulators for treatment of inflammatory and autoimmune diseases)

RN 856937-05-8 HCAPLUS

CN 5-Pyrimidinecarboxamide, N-[(3R)-3-[4-[[4-(4-(aminocarbonyl)phenoxy)phenyl](3-thienylmethyl)amino]-1-piperidinyl]butyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:309175 HCAPLUS

DOCUMENT NUMBER: 143:90722

TITLE: Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

AUTHOR(S): Johnson, Michael P.; Barda, David; Britton, Thomas C.; Emkey, Renee; Hornback, William J.; Jagdmann, G. Erik; McKinzie, David L.; Nisenbaum, Eric S.; Tizzano, Joseph P.; Schoepp, Darryle D.

CORPORATE SOURCE: Lilly Research Laboratories, Lilly Corp. Cent., Eli Lilly and Company, IN, 46285, USA

SOURCE: Psychopharmacology (Berlin, Germany) (2005), 179(1), 271-283

CODEN: PSCHDL; ISSN: 0033-3158

PUBLISHER: Springer GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To increase subtype selectivity and provide a novel means to alter receptor function, the authors discovered and characterization potentiators for the metabotropic glutamate 2 receptor (mGlu2). A class of 3-pyridylmethylsulfonamides (e.g., 3-MPPTS; 2,2,2-trifluoro-N-[3-(2-methoxyphenoxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide) were found to be potent, subtype-selective potentiators of human and rat mGlu2. The sulfonamides increased agonist potency in functional assays but did not displace orthosteric radiolabeled antagonist or agonist binding to cloned mGlu2 receptors. Rather, the modulators increased the affinity of most of the orthosteric agonists including glutamate, DCG-IV ((2S,2'R,3'R)-2-(2',3'-dicarboxylcyclopropyl)glycine), and LY354740 (1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicarboxylate monohydrate). In striatal brain slices, LY354740 inhibited evoked excitatory postsynaptic potentials (EPSPs) equally well following either a low- (0.06 Hz) or high (4 Hz)-frequency stimulation of corticostriatal afferents. In contrast, the mGlu2 potentiator cyPPTS (2,2,2-trifluoro-N-[3-(cyclopentyloxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide) inhibited striatal EPSPs only at higher frequencies of stimulation (2 and 4 Hz). Several sulfonamides including 4-MPPTS, 4-APPES (N-[4-(4-carboxamidophenoxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide hydrochloride monohydrate), and/or

10581164

CBiPES (N-[4'-cyano-biphenyl-3-yl]-N-(3-pyridinylmethyl)-ethanesulfonamide hydrochloride) were tested in mGlu2/3 agonist-sensitive rodent model(s) of anxiety and psychosis. As seen with LY354740, both 4-MPPTS and 4-APPEs were efficacious in a rat fear-potentiated startle paradigm. Likewise in mice, CBiPES attenuated a stress-induced hyperthermia and PCP-induced hyperlocomotor activity. Furthermore, CBiPES mediated alteration in PCP-induced hyperlocomotor activity was sensitive to mGlu2/3 antagonist pretreatment. Taken together, the data indicate mGlu2 receptor potentiators have a unique use-dependent effect on presynaptic glutamate release, and show efficacy in several mGlu2/3-sensitive animal models of psychiatric disorders.


IT 856702-39-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mGlu2 receptor potentiators on presynaptic glutamate release in preclin. anxiety and psychosis models)

RN 856702-39-1 HCAPLUS

CN Benzamide, 4-[4-[(ethylsulfonyl)(3-pyridinylmethyl)amino]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:267241 HCAPLUS

DOCUMENT NUMBER: 140:303538

TITLE: Preparation of [[(aminoalkyl)aryl]oxy]nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions

INVENTOR(S): Blanco-Pillado, Maria-Jesus; Chappell, Mark Donald; Garcia De la Torre, Marta; Diaz Buezo, Nuria; Fritz, James Erwin; Holloway, William Glen; Matt, James Edward, Jr.; Mitch, Charles Howard; Pedregal-Tercero, Concepcion; Quimby, Steven James; Siegel, Miles Goodman; Smith, Dana Rae; Stucky, Russell Dean; Takeuchi, Kumiko; Thomas, Elizabeth Marie; Wolfe, Chad Nolan

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 559 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



Updated Search

10581164

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026305	A1	20040401	WO 2003-US26300	20030917
WO 2004026305	A9	20040513		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499690	A1	20040401	CA 2003-2499690	20030917
AU 2003269980	A1	20040408	AU 2003-269980	20030917
BR 2003014308	A	20050705	BR 2003-14308	20030917
EP 1562595	A1	20050817	EP 2003-751877	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681498	A	20051012	CN 2003-822241	20030917
JP 2006511474	T	20060406	JP 2004-537682	20030917
US 2006217372	A1	20060928	US 2005-526960	20050303
IN 2005KN00457	A	20060303	IN 2005-KN457	20050318
NO 2005001871	A	20050418	NO 2005-1871	20050418
PRIORITY APPLN. INFO.:			US 2002-412158P	P 20020919
			WO 2003-US26300	W 20030917

OTHER SOURCE(S): MARPAT 140:303538
 GI



AB Title diaryl ethers I [wherein X1-X10 = independently C, CH, or N; provided that each of rings A or B has no more than 2 N atoms; E = O or

Updated Search

NH; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, (aryl)heterocyclyl, (cyclo)alkylheterocyclyl, (cyclo)alkanoylalkyl, aroylalkyl, aryloxyalkyl, benzhydryl, bicyclyl(alkyl), benzoyl(alkyl), alkoxyalkyl, alkoxycarbonyl, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, cycloalkylalkyl, carboxyalkyl, carbamoylalkyl, etc.; R3 and R3' = independently H, alkyl, alkenyl, alkynyl, (alkyl)aryl, or alkylcycloalkyl; R4 and R5 = independently H, (halo)alkyl, alkenyl, alkynyl, alkoxy(halo)alkyl, thioalkyl, halo, aryl(alkyl), alkanoyl, alkoxycarbonyl, aminoalkyl, cycloalkylalkyl, etc.; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, alkanoyl, OH, alkoxy, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, aryl(alkyl), carbamoyl(alkyl), etc.; m = 1-3; n = 0-3; p = 0-3; or pharmaceutically acceptable salts, solvates, enantiomers, racemates, diastereomers, or mixts. thereof] were prepared as μ -, κ -, and δ -opioid receptor antagonists. For example, reductive amination of 6-(2-fluoro-4-formylphenoxy)nicotinamide and 3-methylbutylamine provided II (99%). The latter inhibited ex vivo binding of [3H]-diprenorphine in rat striatum/nucleus accumbens by >65% at a concentration of 7 mg/kg. In an acute feeding rat obesity assay, II

suppressed

opioid receptors at a dose of 0.3 μ g/kg. In addition, diet-induced obese rats achieved an energy balance (caloric intake minus utilization) of -81 kcal/kg/day upon administration of 0.3 mg/kg p.o. of II in an indirect calorimetry assay. Thus, I and their pharmaceutical comps. are useful for the treatment, prevention, or amelioration of obesity and related diseases.


IT 676495-22-0P, 4-[4-(3-Phenylpropylamino)phenoxy]benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)

RN 676495-22-0 HCAPLUS

CN Benzamide, 4-[4-[(3-phenylpropyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:17852 HCAPLUS

DOCUMENT NUMBER: 140:71038

TITLE: Pharmaceutical compositions containing aliphatic N-containing 5-membered compounds as dipeptidylpeptidase IV (DPPIV) inhibitors

INVENTOR(S): Yasuda, Kosuke; Morimoto, Keiji; Kanan, Saburo; Hikota, Masaki; Matsumoto, Takeshi; Arakawa, Kenji

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan


SOURCE: Jpn. Kokai Tokkyo Koho, 129 pp.

CODEN: JKXXAF

10581164

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004002367	A	20040108	JP 2003-101361	20030404
PRIORITY APPLN. INFO.:			JP 2002-102757	A 20020404
OTHER SOURCE(S):	MARPAT	140:71038		
GI				



AB The compns., useful for prevention and treatment of type 2 diabetes, contain the compds. I [A = CH₂, S; R₁ = H, lower alkyl, hydroxyalkyl, alkoxyalkyl; R₂ = (un)substituted mono-, di-, or tricyclic hydrocarbyl, heterocyclyl, (un)substituted amino] or their salts. I.HCl (A = CH₂, R₁ = H, R₂ = NMe₂) in vitro inhibited human blood serum DPPIV with IC₅₀ of 3 nM.

IT 412286-40-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aliphatic N-containing 5-membered compds. as dipeptidylpeptidase IV inhibitors)

RN 412286-40-9 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[[cis-4-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-4-methylcyclohexyl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

Updated Search

10581164

L18 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2002:293616 HCAPLUS
DOCUMENT NUMBER: 136:325560
TITLE: Preparation of aliphatic nitrogenous five-membered ring compounds as dipeptidyl peptidase IV inhibitors
INVENTOR(S): Yasuda, Kosuke; Morimoto, Hiroshi; Kawanami, Saburo; Hikota, Masataka; Matsumoto, Takeshi; Arakawa, Kenji
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030891	A1	20020418	WO 2001-JP8803	20011005
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PH, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 200194197	A	20020422	AU 2001-94197	20011005
JP 2002356471	A	20021213	JP 2001-309558	20011005
JP 2002356472	A	20021213	JP 2001-309559	20011005
CA 2424600	A1	20030402	CA 2001-2424600	20011005
BR 2001014436	A	20030701	BR 2001-14436	20011005
EP 1325910	A1	20030709	EP 2001-974717	20011005
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1468216	A	20040114	CN 2001-816674	20011005
HU 200303391	A2	20040301	HU 2003-3391	20011005
NZ 524974	A	20051028	NZ 2001-524974	20011005
CN 1891689	A	20070110	CN 2006-10077863	20011005
IN 2003KN00303	A	20050311	IN 2003-KN303	20030312
ZA 2003002030	A	20030926	ZA 2003-2030	20030313
NO 2003001490	A	20030602	NO 2003-1490	20030402
US 2004063935	A1	20040401	US 2003-398486	20030404
US 6849622	B2	20050201		
JP 2004035574	A	20040205	JP 2003-368572	20031029
US 2004229926	A1	20041118	US 2004-872442	20040622
US 7160877	B2	20070109		
AU 2004237882	A1	20050106	AU 2004-237882	20041213
JP 2005200427	A	20050728	JP 2005-105732	20050401
PRIORITY APPLN. INFO.:				A 20001006
				A 20001012
				A 20010330
				A3 20011005
				A3 20011005
				A3 20011005
				W 20011005
				A3 20030404

OTHER SOURCE(S): MARPAT 136:325560
GI

Updated Search

10581164



AB Aliphatic nitrogenous five-membered ring compds., (S)-N-(N-cyclohexylglycyl)pyrrolidine-2-carbonitrile and (R)-N-(N-cyclohexylglycyl)thiazolidine-2-carbonitrile, of the general formula (I) or pharmacol. acceptable salts thereof [wherein A is CH₂ or S; R₁ is hydrogen, lower alkyl, hydroxy-lower alkyl, or lower alkoxy-lower alkyl; X is N(R₃), O, or CO; R₃ is hydrogen or lower alkyl; and R₂ is an optionally substituted mono- or bicyclic hydrocarbyl or heterocyclyl group or optionally substituted amino] are prepared. These compds. are useful as dipeptidyl peptidase IV inhibitors for the prevention or treatment of diabetes, in particular type II diabetes (no data). Thus, a solution of (S)-1-bromoacetyl-2-cyanopyrrolidine and N-(5-nitro-2-pyridyl)-trans-1,4-cyclohexanediamine in MeOH/MeCN was stirred at room temperature for 15 h to give, after treatment with 2 N HCl/Et₂O in EtOAc/CHCl₃, (S)-2-cyano-1-[[[trans-4-(5-nitro-2-pyridylamino)cyclohexyl]amino]acetyl]pyrrolidine dihydrochloride.

IT 412286-40-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (S)-N-(N-cyclohexylglycyl)pyrrolidine-2-carbonitriles and (R)-N-(N-cyclohexylglycyl)thiazolidine-2-carbonitriles as dipeptidyl peptidase IV inhibitors for prevention or treatment of diabetes)

RN 412286-40-9 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[[[cis-4-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-4-methylcyclohexyl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L18 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:581845 HCAPLUS

Updated Search

10581164

DOCUMENT NUMBER: 135:152723
TITLE: Preparation of N-phenyl-N-alkylsulfonyl(pyridylmethyl)amines as potentiators of glutamate receptors
INVENTOR(S): Coleman, Darrell Stephen; Jagdmann, Gunnar Erik Junior; Johnson, Kirk Willis; Johnson, Michael Parvin; Large, Thomas Hallett; Monn, James Allen; Schoepp, Darryle Darwin; Tizzano, Joseph Patrick; Barda, David Anthony; Britton, Thomas Charles; Dressman, Bruce Anthony; Fichtner, Michael William; Henry, Steven Scott; Hornback, William Joseph
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 247 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056990	A2	20010809	WO 2001-US643	20010122
WO 2001056990	A3	20020425		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1255735	A2	20021113	EP 2001-906521	20010122
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004006114	A1	20040108	US 2002-182961	20021120
US 6800651	B2	20041005		
PRIORITY APPLN. INFO.:			US 2000-180047P	P 20000203
			US 2000-180089P	P 20000203
			WO 2001-US643	W 20010122
OTHER SOURCE(S):	MARPAT 135:152723			
GI				




AB The title compds. [I; R1 = COR3, CO2R4, SO2R5 (wherein R3 = alkyl, cycloalkyl; R4 = alkyl, cycloalkyl; R5 = alkyl, cycloalkyl, fluorinated alkyl); R2 = H, OH, alkyl, etc.; or two R2 are taken together, on adjacent position, to form a fused cycloalkyl or methylenedioxy ring; R6 = H, alkyl, alkoxy, etc.; X = a bond, CH2, (CH2)2, CH(alkyl); Y = a bond, CH2, (CH2)2, etc.] and their pharmaceutically acceptable salts which are potentiators of metabotropic glutamate receptor function, in particular mGlu2 and/or mGlu3 receptors, and therefore useful in treating migraine, anxiety, epilepsy and schizophrenia, were prepared and formulated. Thus, reductive alkylation of 3-(2-methoxyphenoxy)aniline (preparation given) with pyridine-3-carboxaldehyde in the presence of NaBH4 followed by alkylation of the resulting N-[3-(2-methoxyphenoxy)phenyl]pyrid-3-methylamine with F3CCH2SO2Cl afforded the amine II which showed to act at a site other than the glutamate recognition site to potentiate the effects of glutamate at mGlu receptors (data given).

IT 353233-13-3P 353234-76-1P 353235-43-5P
353235-49-1P 353237-68-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenyl-N-alkylsulfonyl(pyridylmethyl)amines as potentiators of glutamate receptors)

RN 353233-13-3 HCAPLUS


CN Benzamide, 4-[4-[(ethylsulfonyl)(3-pyridinylmethyl)amino]phenoxy]-, hydrochloride (10:11) (9CI) (CA INDEX NAME)

10581164




● 11/10 HCl

RN 353234-76-1 HCAPLUS
CN Benzamide, 4-[4-[(ethanesulfonyl) (3-pyridinylmethyl) amino]phenoxy]-3-fluoro-
, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 353235-43-5 HCAPLUS
CN Benzamide, 4-[4-[(ethanesulfonyl) (3-pyridinylmethyl) amino]phenoxy]- (9CI)
(CA INDEX NAME)




RN 353235-49-1 HCAPLUS
CN Benzamide, 4-[4-[(ethanesulfonyl) (3-pyridinylmethyl) amino]phenoxy]-3-fluoro-

Updated Search


10581164

(9CI) (CA INDEX NAME)



RN 353237-68-0 HCAPLUS

CN Benzamide, 3-fluoro-4-[4-[(3-pyridinylmethyl) [(2,2,2-trifluoroethyl)sulfonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



=>

Updated Search